
Opthea Limited
ASX:OPT.AX
1.13 (AUD) • At close February 7, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Opthea Limited |
Symbool | OPT.AX |
Munteenheid | AUD |
Prijs | 1.125 |
Beurswaarde | 1,385,156,250 |
Dividendpercentage | 0% |
52-weken bereik | 0.335 - 1.165 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Megan Baldwin M.A.I.C.D., MAICD, Ph.D. |
Website | https://opthea.com |
An error occurred while fetching data.
Over Opthea Limited
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (AUD)
Cijfers zijn in miljoenen (AUD)